New combination therapy could help fight difficult-to-treat cancers with common mutations
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective…
Browsing: BRAF
Researchers target thyroid cancer with triple threat drug combination
Combining a gene-targeted drug, a cancer-bursting virus and a drug that removes the immune system’s…
Long-term survival rate for subset of patients with advanced melanoma following BRAF- and MEK-targeted treatment combination higher than historical rate
According to the National Cancer Institute’s SEER data, the five-year survival rate for metastatic melanoma among…
Update on Genetic Testing in Cancer and Targeted Therapy
Cancer, a leading cause of mortality, is associated with aberrant genes. Many of the most…
ESMO 2019: New combination therapy offers bowel cancer patients extra treatment option
Based on scientific findings of the Netherlands Cancer Institute a new combination treatment has been…
New research gives hope in the fight against pancreatic cancer
Mariano Barbacid, Centro Nacional de Investigaciones Oncológicas CNIO Pancreatic ductal adenocarcinoma (PDAC), the most common…
ASCO 2019: NCI-MATCH trial finds the combination of dabrafenib and trametinib effective
Treatment with dabrafenib and trametinib, a drug combination designed to target cancers that harbour certain…
BRAF protein modification could slow tumour growth
The protein BRAF is a key player in the development of many different types of…
Combo T cell and targeted therapy strategy for resistant melanoma with BRAF mutation
Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted…
Targeting gene mutations to treat ovarian cancers
New research has shown that ovarian cancer patients with a tumour mutation in the BRAF…